Pharmacogenetics of asparaginase in acute lymphoblastic leukemia

Abstract

Asparaginase is a key component in leukemias and lymphomas treatment protocols and is suggested as a treatment for other malignancies in which an amino acid depletion strategy is indicated. Asparaginase intolerance is subject to inter-individual variability and can manifest as hypersensitivity reactions, pancreatitis, thrombosis, as well as metabolic abnormalities, and may affect treatment outcome. Pharmacogenetics aims at enhancing treatment efficacy and safety by better understanding the genetic basis of variability and its effect on the pharmacological responses. Many groups tried to tackle the pharmacogenetics of asparaginase but the potential implementation of such findings remains debatable. In this review, we highlight the most important findings reported in studies of the pharmacogenetics of asparaginase related complications and treatment outcome in acute lymphoblastic leukemia.

Keywords

Asparaginase / pharmacogenomics / hypersensitivity reactions / pancreatitis / relapse / acute lymphoblastic leukemia / adverse drug reactions

References

[1] Pui CH.A 50-year journey to cure childhood acute lymphoblastic leukemia..Semin Hematol2013;50:185-96 PMCID:PMC3771494

[2] Gervasini G.Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia..Front Genet2012;3:249 PMCID:PMC3504364

[3] Asselin BL,Frantz CN,Leavitt P.In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase..Cancer Res1989;49:4363-8

[4] Fernandez CA,Yang W,Bashford D.HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies..Blood2014;124:1266-76 PMCID:PMC4141516

[5] Mei L,Griffiths EA,Wang ES.Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy..Blood Rev2015;29:243-9 PMCID:PMC4494870

[6] Alachkar H,Sanford B,Mutonga M.Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia..Pharmacogenomics J2017;17:274-9 PMCID:PMC5089920

[7] Paugh SW,Evans WE.Pharmacogenomics in pediatric leukemia..Curr Opin Pediatr2010;22:703-10 PMCID:PMC3612020

[8] Lopez-Santillan M,Martin-Guerrero I,Garcia-Orad A.Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene..Drug Metab Pers Ther2017;32:1-9

[9] Kutszegi N,Gezsi A,Nagy V.Subgroups of paediatric acute lymphoblastic leukaemia might differ significantly in genetic predisposition to asparaginase hypersensitivity..PLoS One2015;10:e0140136 PMCID:PMC4601692

[10] Ben Tanfous M,Ceppi F,Gagne V.Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia..Clin Cancer Res2015;21:329-34 PMCID:PMC4258187

[11] Siegel R,Jemal A.Cancer statistics, 2013..CA Cancer J Clin2013;63:11-30

[12] Schmiegelow K,Mogensen SS,Wolthers BO.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy..F1000Res2017;6:444 PMCID:PMC5389408

[13] Pui CH,Evans WE.Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?.Blood2012;120:1165-74 PMCID:PMC3418713

[14] Cheok MH,Kager L.Pharmacogenetics in acute lymphoblastic leukemia..Semin Hematol2009;46:39-51 PMCID:PMC2665795

[15] Wolthers BO,Abrahamsson J,Helt LR.Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol..Leukemia2017;31:325-32

[16] Zhang G.Personalized medicine: genetic risk prediction of drug response..Pharmacol Ther2017;175:75-90 PMCID:PMC5653378

[17] Abaji R.Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response..Pharmgenomics Pers Med2017;10:143-56 PMCID:PMC5428801

[18] Rousseau J,Labuda M,Sinnett D.ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia..Blood2011;118:5883-90 PMCID:PMC3342855

[19] Chen SH,Fan Y,Crews KR.A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity..Leukemia2011;25:66-74 PMCID:PMC3097057

[20] Aslanian AM.Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells..Biochem J2001;358:59-67 PMCID:PMC1222032

[21] Sugimoto K,Fujimura T,Kaga N.A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines..Cancer Sci2015;106:1534-43 PMCID:PMC4714686

[22] Pui CH.Central nervous system disease in hematologic malignancies: historical perspective and practical applications..Semin Oncol2009;36:S2-16 PMCID:PMC2805279

[23] Tram Henriksen L,Schmiegelow K,Skov Wehner P.Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation..Pediatr Blood Cancer2017;64:

[24] Nguyen HA,Zhang JY.A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias In Vivo..Cancer Res2018;78:1549-60 PMCID:PMC5856643

[25] Chen SH,Yang W,Jeha S.Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity..Clin Pharmacol Ther2010;88:191-6 PMCID:PMC3000799

[26] Kawedia JD,Pei D,Cai X.Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia..Blood2011;117:2340-7quiz 556 PMCID:PMC3062406

[27] Kawedia JD,Pei D,Fernandez CA.Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia..Blood2012;119:1658-64 PMCID:PMC3286344

[28] Liu C,Kawedia JD,Cai X.Asparaginase potentiates glucocorticoid-induced osteonecrosis in a mouse model..PLoS One2016;11:e0151433 PMCID:PMC4788417

[29] Castro-Pastrana LI,Rieder MJ,Hayden M.Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS)..J Popul Ther Clin Pharmacol2011;18:e106-20

[30] Fernandez CA,Yang W,Qu C.Genome-wide analysis links NFATC2 with asparaginase hypersensitivity..Blood2015;126:69-75 PMCID:PMC4492197

[31] Rajic V,Goricar K.Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia..Leuk Lymphoma2015;56:3103-8

[32] Kutszegi N,Gezsi A.HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia..Haematologica2017;102:1578-86 PMCID:PMC5685222

[33] Hojfeldt SG,Tulstrup M.Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008..Br J Haematol2019;184:405-17

[34] Kumar S,Werlin S,Barth B.Risk factors associated with pediatric acute recurrent and chronic pancreatitis: lessons from INSPPIRE..JAMA Pediatr2016;170:562-9 PMCID:PMC5317277

[35] Liu C,Devidas M,Pei D.Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia..J Clin Oncol2016;34:2133-40 PMCID:PMC4962704

[36] Witt H,Rosendahl J,Chandak GR.Variants in CPA1 are strongly associated with early onset chronic pancreatitis..Nat Genet2013;45:1216-20 PMCID:PMC3909499

[37] Derikx MH,Scholz M,Chen JM.Polymorphisms at PRSS1-PRSS2 and CLDN2-MORC4 loci associate with alcoholic and non-alcoholic chronic pancreatitis in a European replication study..Gut2015;64:1426-33

[38] Lee YJ,Choi JH,Kim GH.High incidence of PRSS1 and SPINK1 mutations in Korean children with acute recurrent and chronic pancreatitis..J Pediatr Gastroenterol Nutr2011;52:478-81

[39] Sobczynska-Tomaszewska A,Oralewska B,Norek A.Analysis of CFTR, SPINK1, PRSS1 and AAT mutations in children with acute or chronic pancreatitis..J Pediatr Gastroenterol Nutr2006;43:299-306

[40] Tanaka Y,Kawaguchi T,Hasegawa D.The association between L-asparaginase hypersensitivity and genetic variants in Japanese childhood ALL patients..Blood2016;128:5141

[41] Abaji R,Xu CJ,Ceppi F.Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients..Oncotarget2017;8:43752-67 PMCID:PMC5546438

[42] Karol SE,Cheng C,Yang W.Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia..Leukemia2017;31:1325-32 PMCID:PMC5462853

[43] Place AE,Vrooman LM,Hunt SK.Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial..Lancet Oncol2015;16:1677-90

[44] Pui CH,Pei D,Sandlund JT.Treating childhood acute lymphoblastic leukemia without cranial irradiation..N Engl J Med2009;360:2730-41 PMCID:PMC2754320

[45] Conter V,Parasole R,Locatelli F.Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study..Blood2014;123:1470-8

[46] Stary J,Campbell M,Dibar E.Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002..J Clin Oncol2014;32:174-84

[47] Larsen EC,Chen S,Raetz EA.Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from children’s oncology group study AALL0232..J Clin Oncol2016;34:2380-8 PMCID:PMC4981974

[48] Bowman WP,Devidas M,Blach L.Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children’s Oncology Group trial P9906..Pediatr Blood Cancer2011;57:569-77 PMCID:PMC3136564

[49] Marshall GM,Sutton R,de Groot-Kruseman HA.High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation..Leukemia2013;27:1497-503

[50] Yang JJ,Devidas M,Fan Y.Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia..Nat Genet2011;43:237-41 PMCID:PMC3104508

[51] Yang JJ,Devidas M,Campana D.Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia..Blood2012;120:4197-204 PMCID:PMC3501717

[52] Silverman LB,Dalton VK,Barr RD.Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01..Blood2001;97:1211-8

[53] Pession A,Masera G,Magyarosy E.Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia..J Clin Oncol2005;23:7161-7

[54] Pastorczak A,Zalewska-Szewczyk B,Lejman M.Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment..Leuk Res2014;38:180-3

[55] Schotte D,Akbari Moqadam F,Lange-Turenhout E.MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia..Haematologica2011;96:703-11 PMCID:PMC3084917

[56] Mei Y,Wang K,Li W.Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia..Cancer Sci2014;105:463-72 PMCID:PMC4317805

[57] Mesrian Tanha H,Rahgozar S,Honardoost MA.Integrative computational in-depth analysis of dysregulated miRNA-mRNA interactions in drug-resistant pediatric acute lymphoblastic leukemia cells: an attempt to obtain new potential gene-miRNA pathways involved in response to treatment..Tumour Biol2016;37:7861-72

[58] Friedman RC,Burge CB.Most mammalian mRNAs are conserved targets of microRNAs..Genome Res2009;19:92-105 PMCID:PMC2612969

[59] Krejci O,Otova B,Kalinova M.Upregulation of asparagine synthetase fails to avert cell cycle arrest induced by L-asparaginase in TEL/AML1-positive leukaemic cells..Leukemia2004;18:434-41

[60] Escherich G,Gobel U,Pekrun A.The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97)..Haematologica2011;96:854-62 PMCID:PMC3105647

[61] Wellmann R,Danahey K,Polite BN.Analyzing the clinical actionability of germline pharmacogenomic findings in oncology..Cancer2018;124:3052-65 PMCID:PMC6354920 [Available on 2019-07-15]

[62] Cui H,Natsuisaka M,Asaka M.Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin..Cancer Res2007;67:3345-55

[63] Lorenzi PL,Rudelius M,Shankavaram U.Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells..Mol Cancer Ther2006;5:2613-23

[64] Samudio I.Asparaginase unveils glutamine-addicted AML..Blood2013;122:3398-400

[65] Tardito S,Bozzetti C,Rotoli BM.The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase..Cancer Chemother Pharmacol2007;60:751-8